MKEA.PA
Latest Trade
1.10EURChange
0.00(+0.36%)Volume
776,678Today's Range
-
1.1852 Week Range
-
2.59As of on the Euronext Paris ∙ Minimum 15 minute delay
Previous Close | 1.10 |
|---|---|
Open | 1.12 |
Volume | 776,678 |
3M AVG Volume | 5.33 |
Today's High | 1.18 |
Today's Low | 1.06 |
52 Week High | 2.59 |
52 Week Low | 0.84 |
Shares Out (MIL) | 25.16 |
Market Cap (MIL) | 23.70 |
Forward P/E | -1.97 |
Dividend (Yield %) | -- |
Mauna Kea Technologies Participates In Consortium That Was Awarded EUR 5.4 Million
Mauna Kea Technologies Q3 Sales Down 7% To 1.79 Million Euros
Mauna Kea Technologies H1 Revenue Up At 4.5 Million Euros
Mauna Kea Technologies SAS, also known as Mauna Kea Technologies SA, is a France-based company active in the healthcare business sector. It specializes in designing, developing, and selling medical imaging tools and systems. The Company’s products, used mainly in endoscopy, are intended for viewing and detecting deficiencies in the gastrointestinal and respiratory systems, primarily focusing on patients suffering from cancer. The main product offered by the Company is Cellvizio, a probe-based Confocal Laser Endomicroscopy (pCLE) which is a system providing physicians and researchers with high resolution cellular images of tissue in a real-time structure. The Company has marketing authorizations in Thailand, the United Kingdom, the USA, Brazil, Chile, South Korea, Poland, Russia and Saudi Arabia, among others.
Industry
Medical Equipment & Supplies
Executive Leadership
Sacha Loiseau
Chairman of the Board
Robert L. Gershon
Chief Executive Officer, Director
Christophe Lamboeuf
Deputy Chief Executive Officer, Chief Financial Officer
Francois Lacombe
Chief Scientific Officer
Bruno Villaret
Vice President of International Sales
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 2.97 |
Price To Book (MRQ) | 77.82 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 1,925.08 |
LT Debt To Equity (MRQ) | 1,015.41 |
Return on Investment (TTM) | -133.95 |
Return on Equity (TTM) | -76.99 |
* Q1 TOTAL SALES EUR 1.0 MILLION VERSUS EUR 1.6 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* MAUNA KEA TECHNOLOGIES’ CELLVIZIO® DEMONSTRATES SUPERIOR IDENTIFICATION OF PATIENTS AT RISK FOR ESOPHAGEAL CANCER COMPARED TO CURRENT DIAGNOSTIC STANDARD
* MAUNA KEA TECHNOLOGIES APPOINTS CHRISTOPHE LAMBOEUF, AN EXPERIENCED FINANCIAL EXECUTIVE, AS CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom:)
* FY NET LOSS EUR 10.2 MILLION VERSUS LOSS EUR 9.7 MILLION YEAR AGO
* ANNOUNCES CELLVIZIO RECEIVES POSITIVE EVALUATION FROM KOREAN HEALTH AUTHORITY
* MAUNA KEA TECHNOLOGIES APPOINTS OLIVIER REGNARD AS DEPUTY CEO AND CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* ANNOUNCED ON TUESDAY THAT UROLOGY DIVISION OF COOK MEDICAL HAS OFFICIALLY LAUNCHED WORLDWIDE COMMERCIALIZATION OF CELLVIZIO AS PART OF THE STRATEGIC PARTNERSHIP ANNOUNCED BY THE TWO COS AT END OF 2015
* SAYS MULTICENTER RANDOMIZED CONTROLLED TRIAL SHOWS IMPROVED EARLY STOMACH CANCER DETECTION WITH CELLVIZIO Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* MAUNA KEA TECHNOLOGIES: NEW PUBLICATION CONFIRMS BENEFITS OF USING CELLVIZIO FOR CHARACTERIZING UPPER URINARY TRACT CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Mauna Kea Technologies announces new peer-reviewed publication reports further external validation of unmatched Cellvizio endomicroscopy performance and inter-observer agreement in the characterization of pancreatic cysts
* Mauna Kea Technologies secures a 7.0 million euros ($7.49 million) debt financing Source text for Eikon:
* Mauna Kea technologies appoints John Soto as chief operating officer
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.